The Series B funding is comprised of preferred stock and venture debt.
Mederi Therapeutics manufactures and markets medical devices that use radiofrequency energy to treat digestive system diseases. The Series B funding will be used to support the use of Mederi’s Stretta therapy for gastroesophageal reflux disease and Secca therapy for bowel incontinence.
More Articles on Supply Chain:
Reducing Supply Chain Costs
First Navio Unicondylar Knee Replacement Performed in France
Abrams Royal Pharmacy Issues Voluntary Recall on All Unexpired Sterile Products
